MAPK14 and chronic myelogenous leukemia, BCR-ABL1 positive: In vitro, experimental data showed a nonnecrotic growth limitation of K562 cells caused by α-viniferin was predicted to target Bcl-2, caspase-3, 8, and 9, MAPK14, CDK2, HSP90AA1, and others, reflecting CML therapeutic strategies.